Cybin Reports 100% Response Rate, 71% Remission in Phase 2 Trial for CYB003; Stock Up 20.7%

Nov 18, 2024, 12:08 PM

Cybin Inc. has announced positive results from its Phase 2 clinical trial for CYB003, a treatment for Major Depressive Disorder (MDD). The trial revealed that 100% of participants responded to the treatment, with 71% achieving remission after just two doses of 16 mg each over a 12-month period. Following these promising results, Cybin has initiated the Phase 3 PARADIGM TM multinational pivotal program to further evaluate the efficacy and safety of CYB003. The stock price of Cybin has seen a pre-market increase of 20.7% as a result of this announcement.